Azacitidine (Onureg)

Small molecule

Also known as CC-486, BMS-986345

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (6)
Acute Myeloid Leukemia
NCT04173533 · University of Birmingham
2019-06-14 – 2026-04-29 · Acute Myeloid Leukemia, Myelodysplasia
What this study did
Other / comorbidity
NCT03593018 · The Lymphoma Academic Research Organisation
2018-11-09 – 2025-08-28 · Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT04799275 · National Cancer Institute (NCI)
2021-05-20 – 2027-03-01 · Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
Phase 2 (20)
Acute Myeloid Leukemia
NCT06180863 · Yale University
2023-11 – 2029-04 · Acute Myeloid Leukemia
What this study did
NCT05413018 · Bristol-Myers Squibb
2022-08-19 – 2026-10-31 · Leukemia, Myeloid, Acute
What this study did
NCT03493646 · Kirby Institute
2018-05-18 – 2021-09-21 · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
What this study did
Other / comorbidity
NCT04803201 · Alliance for Clinical Trials in Oncology
2021-10-08 – 2027-05-19 · Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
What this study did
NCT04174196 · Memorial Sloan Kettering Cancer Center
2019-11-19 – 2026-11-19 · Plasmacytoma, Plasmacytoma of Bone, Multiple Myeloma
What this study did
NCT02816021 · M.D. Anderson Cancer Center
2017-02-14 – 2026-03-19 · Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
What this study did
NCT02546986 · Celgene
2015-10-09 – 2025-07-07 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02494258 · Celgene
2015-10-22 – 2025-04-14 · Hematologic Neoplasm, Neoplasms, Hematologic Malignancies
What this study did
NCT04806906 · University of Florence
2021-03-24 – 2025-01-24 · MDS, CMML
What this study did
NCT04778410 · Gilead Sciences
2021-06-28 – 2024-03-04 · Myeloid Malignancies
What this study did
NCT02281084 · Celgene
2015-07-06 – 2023-09-14 · Myelodysplastic Syndromes
What this study did
NCT01928576 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2013-11-06 – 2023-04-04 · Non-Small Cell Lung Cancer, Epigenetic Therapy
What this study did
NCT03542266 · Weill Medical College of Cornell University
2018-06-01 – 2022-07-25 · Previously Untreated Peripheral T-cell Lymphoma
What this study did
NCT02900560 · Translational Research in Oncology
2016-12-20 – 2021-05-27 · Epithelial Ovarian Cancer
What this study did
NCT01845805 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-01-10 – 2021-04-09 · Pancreatic Cancer
What this study did
NCT02374099 · Celgene
2015-03-13 – 2017-11-21 · Breast Neoplasms
What this study did
NCT02269943 · Celgene
2015-02-13 – 2017-04-20 · Nasopharyngeal Neoplasms
What this study did
Phase 1/2 (4)
Acute Myeloid Leukemia
Other / comorbidity
NCT05782127 · Groupe Francophone des Myelodysplasies
2023-12-06 – 2028-11 · Untreated Myelodysplastic Syndrome
What this study did
NCT05141682 · Jonathan Brammer
2022-06-29 – 2027-01-30 · T-Cell Large Granular Lymphocyte Leukemia
What this study did
NCT04722601 · University of Chicago
2021-09-01 – 2023-03-31 · Follicular Lymphoma
What this study did
Phase 1 (18)
Acute Myeloid Leukemia
NCT05287568 · University of Colorado, Denver
2022-12-19 – 2029-03 · AML
What this study did
NCT04887857 · Celgene
2021-12-01 – 2024-01-08 · Leukemia, Myeloid, Acute
What this study did
NCT02223052 · Celgene
2014-10-27 – 2018-12-18 · Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
What this study did
NCT00528983 · Celgene
2007-09-11 – 2016-04-05 · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML)
What this study did
NCT01908387 · Celgene Corporation
2013-07 – 2015-07 · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
What this study did
NCT01519011 · Celgene
2012-02-07 – 2015-05-12 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
What this study did
Other / comorbidity
NCT05162976 · City of Hope Medical Center
2022-01-03 – 2027-04-27 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT04447027 · National Cancer Institute (NCI)
2020-12-17 – 2025-12-17 · Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
What this study did
NCT05209295 · Bristol-Myers Squibb
2024-07-12 – 2025-04-20 · Hepatic Insufficiency, Neoplasms
What this study did
NCT04578600 · Joseph Tuscano
2020-10-23 – 2025-02-21 · Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT05065866 · H. Lee Moffitt Cancer Center and Research Institute
2021-11-18 – 2024-04-24 · Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
What this study did
NCT03450343 · Medical University of South Carolina
2019-04-04 – 2024-01-30 · Large B-Cell Diffuse Lymphoma
What this study did
NCT04639843 · National Cancer Institute (NCI)
2022-11-03 – 2022-11-03 · Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
What this study did
NCT02512172 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-02-19 – 2021-11-20 · Colorectal Cancer
What this study did
NCT02343536 · Celgene
2015-04-29 – 2020-01-29 · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
What this study did
NCT01478685 · Celgene
2011-11-29 – 2015-11-17 · Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
What this study did
NCT01545947 · Celgene
2012-05-01 – 2014-12-11 · Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
What this study did
NCT01571648 · Celgene
2012-04-01 – 2013-01-01 · Myelodysplastic Syndromes
What this study did
Phase 4 (1)
Acute Myeloid Leukemia
NCT06370000 · Virginia Commonwealth University
2024-11-07 – 2030-01-31 · Acute Myeloid Leukemia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Acute Myeloid Leukemia
NCT06326697 · Hikma Pharmaceuticals LLC
2024-05-02 – 2025-08-28 · Acute Myeloid Leukaemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Azacitidine (Onureg): this drugApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Decitabine / Tetrahydrouridine (NDec)
Phase 2(overall)
Small moleculeDNMT1 (DNA methyltransferase 1)
not yet graded(overall)
No reviewed efficacy summary in this indication
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 69 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Azacitidine (Onureg) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
March 2027 (2)
Phase 2/3Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma …Active not recruiting
Est. primary completion 2027-03-01 · NCT04799275 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-23 · NCT05287568 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-04-27 · NCT05162976 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma …Recruiting
Est. primary completion 2027-05-19 · NCT04803201 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 4Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-31 · NCT06370000 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2/3Myelodysplastic SyndromesActive not recruiting
Est. primary completion 2028-07-31 · NCT05469737 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT07463768 · CT.gov ↗
What to watch

See the full readout calendar ↗